Nicotine Differences in Smokers

Sponsor
Yale University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05159934
Collaborator
(none)
20
1
2
12.4
1.6

Study Details

Study Description

Brief Summary

The primary aim of this project is to determine the threshold dose of nicotine, which the smokers will be able to differentiate from placebo (saline). Will use IV pulsed-nicotine infusion that closely matches nicotine delivery by inhaled tobacco use (i.e., tobacco cigarette or electronic cigarette), allowing precise and reproducible nicotine delivery. Four nicotine doses (0.1, 0.05, 0.025, and 0.0125 mg nicotine/pulse) which are within the range of nicotine doses that are delivered by cigarettes with very low to regular nicotine content. These doses will be delivered as a cluster of 4 pulsed-nicotine infusions of 2 sec duration with a 28 sec interval between each dose.

Condition or Disease Intervention/Treatment Phase
  • Drug: 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine
  • Drug: Saline
Phase 1

Detailed Description

Twenty participants will have 2 Experimental Session on 2 separate days. Experimental Session 1 will determine if smokers can reliably discriminate 0.1mg nicotine/pulse nicotine from saline. Experimental Session 2 will determine if smokers can discriminate 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine from saline.

Hypothesis: The threshold for discrimination will be 0.05 mg nicotine/pulse and the doses below that (0.025, and 0.0125 mg nicotine/pulse) will be subthreshold.

Exploratory Aim: To explore the relationship between the threshold for subjective drug effects and drug discrimination.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
Twenty participants will have 2 Experimental Session on 2 separate days. Experimental Session 1 will determine if smokers can reliably discriminate 0.1mg nicotine/pulse nicotine from saline. Experimental Session 2 will determine if smokers can discriminate 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine from saline.Twenty participants will have 2 Experimental Session on 2 separate days. Experimental Session 1 will determine if smokers can reliably discriminate 0.1mg nicotine/pulse nicotine from saline. Experimental Session 2 will determine if smokers can discriminate 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine from saline.
Masking:
Double (Participant, Investigator)
Masking Description:
Nicotine dose will be prepared by pharmacy
Primary Purpose:
Health Services Research
Official Title:
Nicotine Discrimination in Smokers
Actual Study Start Date :
Feb 16, 2022
Anticipated Primary Completion Date :
Jan 2, 2023
Anticipated Study Completion Date :
Mar 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Nicotine

Experimental Session 2 will determine if smokers can discriminate 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine from saline.

Drug: Saline
Saline will be use to determine if smokers can discriminate from the nicotine/pulse of nicotine and saline

Placebo Comparator: saline

Saline will compared to different nicotine doses. Nicotine doses: 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine from saline.

Drug: 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine
Determine if smokers can discriminate 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine from saline.

Outcome Measures

Primary Outcome Measures

  1. Drug Effect Questionnaire [over 3 hours]

    Liking effect

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion criteria:
  • Female and male smokers, aged 18 to 65 years veterans and non-veterans who have been smoking tobacco cigarettes for at least a year

  • smoke ≥ 5 cigs/day ;

  • urine cotinine levels > 100 ng/mL consistent with nicotine intake of an active smoker (23)

  • not seeking treatment at the time of the study for nicotine dependence

  • Good health as verified by medical history, screening examination, and screening laboratory tests

  • For women, not pregnant as determined by pregnancy screening, nor breast feeding, and using acceptable birth control methods.

Exclusion criteria:
  • History of major medical or psychiatric disorders that the physician investigator deems as contraindicated for the subject to be in the study

  • regular use of psychotropic medication (antidepressants, antipsychotics, or anxiolytics)

  • current alcohol or substance dependence for any other recreational or prescription drugs other than nicotine

  • use of e-cigarettes more than 10 days in the past 30 days

  • urine drug screening indicating recent illicit drugs use (with the exception of marijuana).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Veterans Affairs Hospital West Haven Connecticut United States 06516

Sponsors and Collaborators

  • Yale University

Investigators

  • Principal Investigator: Mehmet Sofuoglu, M.D.,Ph.D., Yale University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Mehmet Sofuoglu, Professor of Psychiatry, Yale University
ClinicalTrials.gov Identifier:
NCT05159934
Other Study ID Numbers:
  • MS063
First Posted:
Dec 16, 2021
Last Update Posted:
Apr 18, 2022
Last Verified:
Apr 1, 2022
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 18, 2022